KORU Medical Systems to Report First Quarter 2025 Financial Results on May 7, 2025
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in large volume subcutaneous infusion solutions, has announced it will release its first quarter 2025 financial results on Wednesday, May 7, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. U.S. and Canadian participants can join via (877)-407-0784, while international callers should use (201)-689-8560. The webcast will be available on KORU Medical's website and archived for six months.
KORU Medical Systems (NASDAQ: KRMD), un'azienda tecnologica nel settore medico specializzata in soluzioni di infusione sottocutanea ad alto volume, ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 mercoledì 7 maggio 2025.
La società terrà una conference call e una webcast alle 16:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale. I partecipanti dagli Stati Uniti e dal Canada potranno collegarsi chiamando il numero (877)-407-0784, mentre i chiamanti internazionali dovranno utilizzare il numero (201)-689-8560. La webcast sarà disponibile sul sito web di KORU Medical e archiviata per sei mesi.
KORU Medical Systems (NASDAQ: KRMD), una empresa de tecnología médica especializada en soluciones de infusión subcutánea de gran volumen, ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el miércoles 7 de mayo de 2025.
La compañía realizará una llamada conferencia y una transmisión en vivo a las 4:30 p.m. ET el mismo día para analizar los resultados y ofrecer una actualización corporativa. Los participantes de EE. UU. y Canadá podrán unirse marcando el (877)-407-0784, mientras que los llamantes internacionales deben usar el (201)-689-8560. La transmisión estará disponible en el sitio web de KORU Medical y se archivará durante seis meses.
KORU Medical Systems (NASDAQ: KRMD)는 대용량 피하 주입 솔루션을 전문으로 하는 의료 기술 회사로, 2025년 1분기 재무 실적을 2025년 5월 7일 수요일에 발표할 예정이라고 밝혔습니다.
회사는 같은 날 오후 4시 30분 ET에 실적 발표 및 회사 업데이트를 위한 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 미국과 캐나다 참가자는 (877)-407-0784로, 해외 참가자는 (201)-689-8560으로 전화해 참여할 수 있습니다. 웹캐스트는 KORU Medical 웹사이트에서 시청 가능하며 6개월간 아카이브됩니다.
KORU Medical Systems (NASDAQ : KRMD), une entreprise de technologie médicale spécialisée dans les solutions d'infusion sous-cutanée à grand volume, a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le mercredi 7 mai 2025.
La société organisera une conférence téléphonique et une diffusion en direct à 16h30 ET le même jour pour discuter des résultats et fournir une mise à jour d'entreprise. Les participants des États-Unis et du Canada pourront se joindre en composant le (877)-407-0784, tandis que les appelants internationaux devront utiliser le (201)-689-8560. La diffusion sera disponible sur le site web de KORU Medical et archivée pendant six mois.
KORU Medical Systems (NASDAQ: KRMD), ein Medizintechnikunternehmen, das sich auf großvolumige subkutane Infusionslösungen spezialisiert hat, hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 am Mittwoch, den 7. Mai 2025, zu veröffentlichen.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Teilnehmer aus den USA und Kanada können unter (877)-407-0784 teilnehmen, internationale Anrufer wählen bitte (201)-689-8560. Der Webcast wird auf der Webseite von KORU Medical verfügbar sein und für sechs Monate archiviert.
- None.
- None.
Conference Call and Webcast Details
The conference call can be accessed by dialing (877)-407-0784 for participants in the
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250416967991/en/
Investor Contact:
Louisa Smith
investor@korumedical.com
Source: KORU Medical Systems, Inc.
FAQ
When will KORU Medical Systems (KRMD) release Q1 2025 earnings?
How can investors access KORU Medical's Q1 2025 earnings call?
How long will KORU Medical's Q1 2025 earnings webcast be available?
What is KORU Medical Systems' (KRMD) main business focus?
